Loading
A phase 2 trial of Denileukin diftitox in Melanoma, run by James Graham Brown Cancer Center, completed.
Phase II Trial of Ontak With Metastatic Melanoma is a phase 2 interventional study registered as NCT00299689 by James Graham Brown Cancer Center, with 69 participants recorded, started 2006-03 and reaching its primary completion in 2010-01. Interventions recorded: Denileukin diftitox. Conditions recorded: Malignant Melanoma.
Linked to the drug Denileukin diftitox because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
69 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2014-09-05), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Positive Response Defined as Clinical Complete Response, Partial Response or Stable Disease (Persisting for at Least 4 Weeks) as Measure by Modified RECIST Criteriaprimary | Intervention | 16 | 16 participants | - | - | link |
Shares Denileukin diftitox, Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Denileukin diftitox and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.